[{"orgOrder":0,"company":"Acrotech Biopharma","sponsor":"Onxeo","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Belinostat","moa":"HDAC","graph1":"Oncology","graph2":"Approved","graph3":"Acrotech Biopharma","amount2":0.01,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Acrotech Biopharma \/ Acrotech Biopharma","highestDevelopmentStatusID":"12","companyTruncated":"Acrotech Biopharma \/ Acrotech Biopharma"},{"orgOrder":0,"company":"Acrotech Biopharma","sponsor":"CASI Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Pralatrexate","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Acrotech Biopharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Acrotech Biopharma \/ CASI Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Acrotech Biopharma \/ CASI Pharmaceuticals"}]

Find Clinical Drug Pipeline Developments & Deals by Acrotech Biopharma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : The partnership aims for the manufacturing and advancement of iTolerance's Streptavidin-FasL (SA-FasL) fusion protein, a crucial component of the proprietary iTOL-100 platform technology towards first in human clinical study for lead program, iTOL-102.

                          Brand Name : Folotyn

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          August 01, 2023

                          Lead Product(s) : Pralatrexate

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Sponsor : CASI Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          02

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : The new Agreement grants Acrotech a royalty-free license to belinostat in all other territories including the United States, Canada, Mexico, and India.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : $6.6 million

                          April 06, 2020

                          Lead Product(s) : Belinostat

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Recipient : Onxeo

                          Deal Size : $6.6 million

                          Deal Type : Agreement

                          blank